Business Wire

Brand Jamaica to Shine at Penn Relays

27.4.2022 21:00:00 EEST | Business Wire | Press release

Share

Brand Jamaica will be highlighted at the 126th staging of the Penn Relays, which will be held from April 28-30, 2022, in Philadelphia, Pennsylvania. Five Jamaican manufacturers, Annilu Limited, Herboo, King’s Jamaican Health and Wellness, Bresheh, and Shavuot International, will interact with buyers, distributors, and retailers to promote their products with the aim of increasing Jamaica’s export sales.

The trade mission is taking place as part of the export development programme Export Max III, which is led by JAMPRO, the Jamaica Business Development Corporation (JBDC), and the Jamaica Manufacturers and Exporters Association (JMEA). The event will highlight the island’s diverse manufacturing sector, and the products that are available for export.

Jamaica’s Prime Minister, The Most Honourable Andrew Holness, and Minister of Industry, Investment, and Commerce, Senator the Honourable Aubyn Hill, will attend the Penn Relays. The event will feature a pavilion designed to house the Jamaican companies that will facilitate engagement with the over 100,000 patrons that are expected to attend the event. B2B (Business-to-Business) meetings will also take place to support the companies during the trade mission, as they look to build meaningful business relationships in the United States.

The Penn Relays are a great avenue for the promotion of Brand Jamaica because of its high profile as a major event and its historical connection with Jamaica, our athletes, and the diaspora,” explained Minister Hill. “The event therefore provides an opportunity for Jamaica to not only display amazing athletic performances, but to connect with the Jamaican Diaspora expected to attend the event, and will introduce products to buyers and retailers in that area who are interested in securing ethnic food and other goods for their markets.”

The government is also encouraging Jamaicans abroad to invest in agro-processing, skills training, and in logistics, particularly Jamaica’s Special Economic Zones.

Penn Relays trade mission critical part of developing Jamaica’s exports

The mission will be a critical step in Jamaica’s ongoing efforts to identify new export opportunities for manufacturers, establish Jamaica as a supplier of high-quality products, and to increase the international exposure of the country’s exporters. It is one of the island’s major trade executions since the COVID-19 pandemic and is expected to give a boost to the Export Max participants.

Diane Edwards, President of JAMPRO said, “This particular event is expected to generate significant leads for our exporters, and should help them to secure contractual arrangements with targeted US distributors. While this will not be the first time that Jamaica has had major activities at the Penn Relays, I believe that there are advantages to this edition, as this will be the first staging of the competition since the onset of the COVID-19 pandemic. There is also a joyous mood surrounding the event, as it falls in the same year of Jamaica's 60th Anniversary as an independent nation.”

Edwards insisted that the event will reinforce Jamaica’s image as a source of high-quality exports, and will serve many purposes for the manufacturers, as well as buyers. She said, “The companies that will be at the Penn Relays represent the high quality and diversity of Jamaican products, and this initiative will give them the opportunity to be on the world stage and reach new audiences. For the buyers, it will introduce them to Jamaican exporters, and will show them the vast range of products that we have to offer. We believe that this mission will be fruitful for all the participants and stakeholders, and we look forward to seeing the positive impact it will have on the Jamaican economy.”

The Jamaica Promotions Corporation’s (JAMPRO’s) mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tamica Parchment
Integrated Marketing Communications
tparchment@jamprocorp.com
Tele: 876-978-7755

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye